Related references
Note: Only part of the references are listed.De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017)
G. Curigliano et al.
ANNALS OF ONCOLOGY (2018)
Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes
Scott Kizy et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers
Andre Filipe Vieira et al.
FRONTIERS IN MEDICINE (2018)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer
Jesse L. Felts et al.
BREAST JOURNAL (2017)
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation
Luisa Carbognin et al.
BREAST (2017)
Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
Scott Kizy et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
Salomon M. Stemmer et al.
NPJ BREAST CANCER (2017)
Relative Effectiveness of Adjuvant Chemotherapy for Invasive Lobular Compared With Invasive Ductal Carcinoma of the Breast
Schelomo Marmor et al.
CANCER (2017)
Outcomes in Patients With Early-Stage Breast Cancer Who Underwent a 21-Gene Expression Assay
Carlos H. Barcenas et al.
CANCER (2017)
Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer
W. Truin et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma
Michaela L. Tsai et al.
CLINICAL BREAST CANCER (2016)
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer
Joan Albanell et al.
EUROPEAN JOURNAL OF CANCER (2016)
Comparison of SEER Treatment Data With Medicare Claims
Anne-Michelle Noone et al.
MEDICAL CARE (2016)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Niamh Conlon et al.
BREAST JOURNAL (2015)
Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival
Antonio Garcia-Fernandez et al.
BREAST JOURNAL (2015)
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics
Amy E. McCart Reed et al.
BREAST CANCER RESEARCH (2015)
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population
Seung Taek Lim et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
Y. Delpech et al.
BRITISH JOURNAL OF CANCER (2013)
Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer
W. Truin et al.
ANNALS OF ONCOLOGY (2012)
Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period
Lucio Fortunato et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007)
William B. Wong et al.
CONTEMPORARY CLINICAL TRIALS (2012)
Utility of Oncotype DX Risk Estimates in Clinically Intermediate Risk Hormone Receptor-Positive, HER2-Normal, Grade II, Lymph Node-Negative Breast Cancers
Catherine M. Kelly et al.
CANCER (2010)
Lobular breast carcinoma and its variants
Emad A. Rakha et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2010)
Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes
Emad A. Rakha et al.
EUROPEAN JOURNAL OF CANCER (2008)
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials
Bernhard C. Pestalozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast
Emad A. Rakha et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?
Upali W. Jayasinghe et al.
BREAST JOURNAL (2007)
Primary systemic chemotherapy of invasive lobular carcinoma of the breast
Artur Katz et al.
LANCET ONCOLOGY (2007)
Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
